Infixion Bioscience is focused on developing innovative drug therapies to address Neurofibromatosis Type 1 (NF1), a genetic disorder that affects approximately 1 in 3000 individuals globally. The company aims to tackle the underlying issue of insufficient Neurofibromin protein, which is crucial for regulating various cellular functions, including cell division and the health of multiple body systems. By enhancing the natural production and maintenance of Neurofibromin, Infixion seeks to mitigate the symptoms and progression of NF1, which can include tumor growth, skin lesions, and increased risks of cancer and cardiovascular diseases.

A significant aspect of Infixion's research involves the development of a new monoclonal antibody designed to accurately detect NF1 protein levels. This antibody is intended to provide a more selective and sensitive measurement tool for neurofibromin, which is essential for evaluating potential drug therapies. Collaborating with Abterra Biosciences and leveraging advanced antibody discovery technologies, Infixion has made strides in creating a superior antibody that outperforms existing options. This advancement is expected to facilitate further research and drug discovery efforts aimed at restoring normal NF1 protein levels, ultimately contributing to effective treatments for individuals affected by NF1.

United States

The mission of iNFixion Bioscience is to develop drug therapies to treat and prevent the progression of all symptoms associated with Neurofibromatosis Type 1 (NF1), a rare genetic disorder impacting approximately 2.5M people worldwide.  

iNFixion's unique approach to NF1 is to correct a key underlying genetic ‘mechanism of action', namely the lack of functional Neurofibromin protein, by enhancing the affected person's natural ability to both produce and maintain healthy Neurofibromin protein. By correcting this root cause mechanism, we believe that a fundamental and preventive impact on disease symptoms, and disease progression, will be achieved.

Infixion Bioscience

Company Details